U.S. Consumer Durables Stock News

Astec Industries (ASTE) reported a major turnaround, achieving profitability for the period and breaking from a trend of 13.5% annual earnings declines over the past five years. While earnings are forecast to accelerate at 28.2% per year, well ahead of the US market's 16%, revenue growth is expected to be slower at 5.2% per year compared to the market’s 10.5%. Investors are weighing the positive earnings outlook against a recent one-off $38.7 million loss that clouds near-term profit clarity...

GoodRx Holdings (GDRX) reported a milestone year as the business turned profitable, posting a positive net profit margin for the first time after several years of expanding earnings. Over the past five years, earnings have surged at an impressive average annual rate of 65.2%, while forecasts point to ongoing earnings growth of 21.5% each year. This outpaces the broader US market. Still, revenue is projected to rise by 6.6% per year, trailing the US market’s 10.5% pace, and investors may weigh...

Personalis (PSNL) remains unprofitable, with losses mounting at a pace of 13.5% per year over the last five years. Despite the ongoing red ink, the company is expected to grow revenue at a rapid 30.32% annually, easily outpacing the broader US market's growth rate of 10.5% per year. Investors are closely watching whether this strong top-line forecast can eventually reverse persistent losses, especially as shares trade at an 8.5x Price-to-Sales Ratio, which is far above both peer and industry...

OmniAb (OABI) remains in the red, with losses climbing at an average rate of 30.8% annually over the past five years and no improvement in net profit margin. The company is expected to stay unprofitable for at least the next three years, ruling out traditional earnings growth comparisons. However, investors are eyeing a forecasted 30.4% annual revenue increase, which is well ahead of the US market's 10.5% average. With persistent unprofitability and high valuation multiples balanced against...

Radian Group (RDN) posted annual earnings growth of 5.1% over the past five years, but its earnings slipped over the last year and are projected to rise only 3.7% annually going forward. Revenue is on track to grow at 6.5% each year, trailing the US market average of 10.5%. The recent net profit margin came in at 45.6%, down from 47.1% last year. Investors may see the lower price-to-earnings ratio of 7.9x as a value opportunity versus its peers. However, growth prospects appear more modest...

DigitalOcean Holdings (DOCN) came in with a forecast of 15.5% annual revenue growth, topping the broader US market forecast of 10.5%. The company’s earnings are expected to climb 22.2% per year, outpacing the national average of 16%, and net profit margins have increased to 15.2% from last year's 9.3%. After a standout year of 84.9% earnings growth and five-year annualized growth of 78.1%, DigitalOcean is establishing itself as a consistently profitable player. See our full analysis for...

Match Group (MTCH) has seen earnings rise 7% per year over the last five years, and profits are forecast to grow at 11.7% per year going forward. Net profit margins in the latest period landed at 15.6%, down from 18.7% a year earlier. Revenue growth is expected to trail the broader market, with forecasts for a 5.4% annual pace compared to the US market’s 10.5%. See our full analysis for Match Group. Next up, we will see how these headline numbers play out against the current narratives and...

CareDx (CDNA) shifted into profitability this quarter, backed by forecasts that call for robust annual earnings growth of about 80.2% and revenue growth of 11.1% per year for the next three years. The company’s $16.53 share price and Price-To-Earnings Ratio of 15.1x compare favorably to industry and peer averages. However, the recent results were buoyed by a significant, non-recurring gain of $89.4 million. With these headline numbers and a valuation still above the estimated fair value of...

Wolverine World Wide (WWW) has recently turned a profit, with its net profit margin improving over the past year. Earnings are forecast to grow an impressive 27.7% per year, outpacing the broader US market's 16% projection. The five-year annual earnings growth sits at 4.6%. With revenue expected to rise 7.1% per year going forward and the shares trading at $16.72, the company delivers high-quality earnings and maintains value metrics that stand out compared to peers. However, its financial...

EyePoint Pharmaceuticals (EYPT) remains unprofitable, with losses increasing at an annual rate of 25.2% over the past five years. While the company is forecast to stay in the red for at least three more years, revenue is projected to surge by 61.3% per year, outpacing the broader US market's expected 10.5% annual growth. Investors are weighing these robust revenue forecasts against ongoing share dilution and persistent unprofitability as they consider EyePoint’s current valuation. See our...

Weyco Group (WEYS) reported a net profit margin of 9.2% for the period, down from 10% last year, reflecting recent pressure on profitability. Despite this, the company stands out for its historically high earnings quality, with five-year annual earnings growth averaging a robust 31.5%. Its shares trade at $31.35, well below an estimated fair value of $90.59. Value-focused investors are likely to take note of its discounted price-to-earnings multiple and appealing dividend, although the latest...

Jones Lang LaSalle (JLL) posted annual revenue growth of 7.2%, trailing the broader US market’s 10.5% pace, while EPS is forecast to grow 15.3% per year, just under the US average of 16%. Over the past year, profit margins moved up from 1.8% to 2.3% and the company swung to positive earnings growth, up 47.4% after several years of decline. With high-quality earnings and valuation metrics below both peer and industry averages, these results could give investors reasons to view JLL’s latest...

Unity Software (U) remains in the red, with losses deepening by 10.8% per year over the past five years and no notable shift in profitability metrics. Revenue is forecast to grow at 10% annually, slightly lagging the broader US market's 10.5%. With shares trading at $42.36, well above the estimated fair value of $36.45 and a price-to-sales ratio of 10.1x that surpasses both peer and industry averages, investors see a company priced for growth but still searching for sustained profits in the...

agilon health (AGL) is expected to post revenue growth of 10.7% per year, slightly outpacing the broader US market’s 10.5% rate. The stock trades at $0.75 per share, which is significantly below its estimated fair value of $13.21 and reflects a substantial discount on key valuation metrics such as its 0.1x Price-to-Sales ratio. Despite this growth outlook, the company remains unprofitable and losses have been increasing by 7.9% annually over the past five years, which continues to put...

Navigator Holdings (NVGS) posted a net profit margin of 15.6%, edging up from 14.8% a year earlier, with earnings growth of 6.7% over the past year following a robust five-year average annual growth of 55.1%. While the company’s price-to-earnings ratio of 12.6x underscores its value orientation compared to US oil and gas peers, shares recently traded at $16.93 and sit above the internally estimated fair value of $2.68. Looking ahead, investors are weighing improved profitability and...

Chord Energy (CHRD) posted net profit margins of 5.3% for the twelve months leading up to September 30, 2025, down sharply from 22.2% a year earlier. This decline was largely driven by a one-off $578 million loss that weighed on earnings results for the period. Looking ahead, investors are weighing the short-term margin pressure and non-recurring losses against robust forward-looking projections. Annual earnings growth of 37.2% is expected and could outpace the broader US market. See our full...

MBIA (MBI) continues to operate at a loss, but over the last five years the company has narrowed those losses at an average annual rate of 3.2%. Despite this gradual progress, MBIA’s net profit margin is still in negative territory, and its valuation stands out. The Price-to-Sales Ratio sits at 3.5x, which is significantly higher than both the US insurance industry average of 1.1x and a peer group average of 1.3x. With profitability still out of reach and no fair value estimate available,...

CeriBell (CBLL) is forecast to grow revenue by 23.39% per year, outpacing the US market’s projected 10.5% annual increase. Despite this trajectory, the company remains unprofitable and is not expected to reach profitability within the next three years, with no evidence of net profit margin improvement over the last twelve months. Investors are likely to weigh CeriBell's robust top-line expansion against continued losses and a valuation multiple well above peers. See our full analysis for...

Stoke Therapeutics (STOK) has moved into profitability over the past year and is now forecasting revenue growth of 20.1% per year, which handily outpaces the broader US market's 10.5% annual growth expectation. However, earnings are projected to decline by 5.6% each year over the next three years, suggesting the company's recently achieved profit status may be tested as the bottom line comes under pressure. The premium valuation and mixed outlook put investor attention squarely on how...

Corsair Gaming (CRSR) reported that losses have deepened at an average rate of 68.9% per year over the past five years, reflecting mounting unprofitability even as the company forecasts 8.7% annual revenue growth, which is below the 10.5% US market average. However, with earnings expected to grow at a robust 96.57% per year and profitability projected within the next three years, Corsair is seen by some investors as a turnaround candidate. See our full analysis for Corsair Gaming. Next up, we...

Solid Power (SLDP) continues to operate at a loss, with net losses deepening at a 50.3% annual rate over the last five years. Despite persistent negative profit margins, analysts forecast revenue growth of 40.5% per year, far outpacing the US market’s 10.5% average and SLDP’s peer group. This high growth outlook is very much in focus as investors weigh it against ongoing losses and a valuation that already sits far above sector averages. See our full analysis for Solid Power. Next, we’ll see...

Astera Labs (ALAB) has just turned profitable, with forecasts calling for earnings to grow at 27.1% per year and revenue to rise 23.5% annually, both comfortably ahead of US market averages. The company’s net profit margin has flipped from negative to positive, and its high quality earnings profile comes as shares are trading at a remarkable premium: a Price-To-Sales ratio of 49.9x, well above both direct semiconductor peers and the industry average. With no major risks or insider selling...

Andersons (ANDE) grew its earnings at an average annual rate of 16.2% over the past five years, recently posting a net profit margin of 0.7% compared to last year's 0.8%. Despite these longer-term gains, the company recorded negative earnings growth for the past year, creating a notable contrast with its historical trajectory. Investors are weighing the company’s profitable track record, slight margin compression, and the possibility that shares trading at $48.48, well below the estimated...

AnaptysBio (ANAB) is forecasting revenue growth of 25.9% per year, ahead of the broader US market’s 10.5% growth rate. Despite this, the company remains unprofitable, with losses climbing at an annual pace of 29.9% over the past five years. Net profit margins and earnings quality have yet to show improvement. Shares currently trade at a Price-to-Sales ratio of 8.2x, which offers better value than the US Biotech sector average of 10.3x, but appears expensive relative to peers at 5.8x. This...